Company

Product

Description

Development Status

Aeterna Laboratories Inc. (MSE, TSE:AEL)

Neovastat (AE941)

Shark cartilage extract with anti-angiogenic and anti-inflammatory activities

NCI-sponsored Phase III slated to begin Fall 1999 (non-small-cell lung cancer)

AnorMED Inc. (TSE:AOM)

Lambda

Lanthanum carbonate; oral drug designed to bind phosphate in the gut

In Phase III trials in dialysis patients

Allelix Biopharmaceuticals Corp. (MSE, TSE:AXB)

ALX1-11

Recombinant human parathyroid hormone

Completed Phase II in osteoporosis

AltaRex Corp. (TSE:AXO)

OvaRex MAb

Anti-idiotype induction therapy-based vaccine; consists of modified murine monoclonal antibody that binds to CA125 cancer antigen

In Phase IIb trials for ovarian cancer

BioChem Pharma (MSE, TSE:BCH; NASDAQ:BCHE)

dOTC (BCH-10652)

HIV/AIDS therapeutic

Currently in Phase II trials; expected to enterpivotal Phase II/III trials in Fall 1999

Biomira Inc. (MSE, TSE:BRA; NASDAQ:BIOM)

Theratope

Synthetic, carbohydrate-based vaccine (mimic of cancer antigen sialyl-Tn plus carrier molecule KLH)

In Phase III trial for metastatic breast cancer

DUSA Pharmaceuticals Inc. (NASDAQ:DUSA)

Levulan Photodynamic Therapy

Light-activated drug; 20 percent solution of amino-levulinic acid HCl (topical)

NDA slated to go before FDA advisory panel 7/99; indication is actinic keratoses of face and scalp

Generex Biotechnology Corp. (OTC BB:GNBT)

Oralin (a.k.a. Oragen)

Liquid (oral) formulation of insulin, administered via metered dose aerosol application

IND approved in the U.S. and Canada to begin Phase II and III trials in diabetes

Ibex Technologies Inc. (MSE, TSE:IBT)

Neutralase

Heparinase-1, a heparin-degrading enzyme (bolus injection)

At Phase III trial stage in bypass surgery

Lorus Therapeutics Inc. (formerly Imutec Pharma Inc.; MSE, TSE:LOR; NASDAQ:LORFF)

Virulizin

Biological response modifier extracted from bovine reticuloendothelium; activates macrophages and stimulates release of tumor necrosis factor-alpha

Phase I/II trials in pancreatic cancer completed; Phase I/II ongoing in Kaposi's Sarcoma; approved in Mexico for malignant melanoma

Micrologix Biotech Inc. (TSE, VSE:MBI)

MBI-226

Antimicrobial peptide, 12 amino-acid analogue of mammalian-derived host-defense peptide for prevention of bloodstream infections in patients undergoing central venous catheterization

Completed 2-part Phase I trial

NovoPharm Biotech Inc. (TSE, VSE:NVO)

NOVOMAb-G2scFv

Single-chain variable fragment of fully human monoclonal antibody; reacts with variety of tumor types

Completed Phase I trial

QLT Phototherapeutics Inc. (MSE,TSE:QLT;NASDAQ:QLTI)

Visudyne

Verteporfin; light-activated drug for photodynamic therapy

In Phase III trials for age-related macular age-related macular degeneration

Synsorb Biotech Inc. (TSE:SYB;NASDAQ:SYBB)

Synsorb Pk

Orally delivered carbohydrate attached to inert, insoluble support; binds to toxins secreted by bacteria in the gastrointestinal tract

In Phase III for E. coli infections and prevention of hemolytic uremic syndrome

Theratechnologies Inc. (MSE, TSE:TH)

Photodynamic cell therapy Process (PDP)

Purges bone marrow tumor cells through ex vivo treatment with photosensitive agent (TH9405)

Safety and efficacy trial under way in Canada for the device-class therapy, which could be marketed by 2000

MSE=Montreal Stock Exchange; TSE=Toronto Stock Exchange; VSE=Vancouver Stock Exchange